Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial

Phase 2negativeNegative

AI Analysis

Summary

Longeveron's stem cell therapy failed in a mid-stage cardiovascular trial, causing share price decline. The company is conducting a strategic review with approximately $10 million in cash remaining to sustain operations through year-end.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

stem cell therapy failed in mid-stage cardiovascular trial

Importance:7/10

Sentiment:

-0.95

stem cell therapycardiovasculartrial failurecash positionstrategic review

Related Companies

$LGVN

Read the original article

Published by BioSpace on September 17, 2026 12:19 PM

Read Original